STUDY OF THE UNREALIZED PREGNANCY IN WOMEN WITH POLYCYSTIC OVARY SYNDROME
Keywords:
unrealized pregnancies, polycystic ovary syndromeAbstract
The number of unrealized pregnancies (miscarriages) in patients is a direct indicator of the state of their reproductive system. That is why we decided to study, compare and analyze the number of spontaneous abortions in women from both groups of our study. Spontaneous abortion in clinically healthy women in early pregnancy is very common. Studies show that in women who know they are pregnant, it occurs between 10-20%, while in fact it is even more common (up to 30%), including very early miscarriages that manifest as delayed menstruation, in which pregnancy has not been established. Of all abortions, 80% are up to 12 gestational week. The incidence of spontaneous abortions in women with polycystic ovary syndrome (PCOS) is higher than in healthy women - over 45%.References
I. D. Harris, S. Wang, L. Roth, R. Alvero, P. McShane, and W. D. Schlaff, When antimullerain hormone and follicle stimulating hormone offer a discrepent prognosis of ovarian reserve, in vitro fertilization outcomes are worse than when both values predict poor ovarian reserve, Fertility and Sterility, vol. 94, supplement, p. S26, 2010.
O. Rustamov, A. Smith, S. A. Roberts et al., Anti-Müllerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability, Human Reproduction, vol. 27, pp. 3085–3091, 2012.
H. Abdallah and Y. Thum, Association of AMH and FSH levels with IVF treatment, Fertility and Sterility, vol. 90, supplement, p. 405, 2008.
N. Gleicher, A. Weghofer, and D. H. Barad, Anti-Müllerian hormone (AMH) defines, independent of age, low versus good live-birth chances in women with severely diminished ovarian reserve, Fertility and Sterility, vol. 94, no. 7, pp. 2824–2827, 2010.
R. K. K. Lee, F. S. Y. Wu, M.-H. Lin, S.-Y. Lin, and Y.-M. Hwu, The predictability of serum anti-Müllerian level in IVF/ICSI outcomes for patients of advanced reproductive age, Reproductive Biology and Endocrinology, vol. 9, article 115, 2011.
N. Gleicher and D. H. Barad, Dehydroepiandrosterone (DHEA) supplementation in diminished ovarian reserve (DOR), Reproductive Biology and Endocrinology, vol. 9, article 67, 2011.
A. Hazout, P. Bouchard, D. B. Seifer, P. Aussage, A. M. Junca, and P. Cohen-Bacrie, Serum anti-Müllerian hormone/Müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle- stimulating hormone, inhibin B, or estradiol, Fertility and Sterility, vol. 82, no. 5, pp. 1323 1329, 2004.
D. N. Lekamge, M. Barry, M. Kolo, M. Lane, R. B. Gilchrist, and K. P. Tremellen, Anti- Müllerian hormone as a predictor of IVF outcome, Reproductive BioMedicine Online, vol. 14, no. 5, pp. 602–610, 2007.
J. M. J. Smeenk, F. C. G. J. Sweep, G. A. Zielhuis, J. A. M. Kremer, C. M. G. Thomas, and D. D. M. Braat, Anti-Müllerian hormone predicts ovarian responsiveness, but not embryo quality or pregnancy, after in vitro fertilization or intracyoplasmic sperm injection, Fertility and Sterility, vol. 87, no. 1, pp. 223–226, 2007.
S. L. Fong, E. B. Baart, E. Martini et al., Anti-Müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality? Reproductive BioMedicine Online, vol. 16, no. 5, pp. 664–670, 2008.
Downloads
Issue
Section
License
New knowledge Journal of science by Univesity of agribusiness and rural development is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Based on a work at http://science.uard.bg/index.php/newknowledge/issue/archive.
Permissions beyond the scope of this license may be available at http://science.uard.bg/index.php/newknowledge/index.
